A Phase 1b Safety and Tolerability Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
Phase of Trial: Phase I
Latest Information Update: 22 Nov 2017
At a glance
- Drugs ZEN 3694 (Primary) ; Enzalutamide
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Zenith Epigenetics Corp
- 10 Jun 2017 Biomarkers information updated
- 15 Jun 2016 According to a Zenith Epigenetics Corp media release, first patient has been dosed in this trial.
- 15 Jun 2016 Status changed from not yet recruiting to recruiting, according to a Zenith Epigenetics Corp media release.